Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 …

Dec 30, 2024 · 8 analysts have expressed a variety of opinions on Axsome Therapeutics (NASDAQ:AXSM) over the past quarter, offering a diverse set of opinions from bullish to …

53%
OFF

Can Axsome Hold Out Till Depression Drug Becomes A Blockbuster?

2 weeks from now

Apr 12, 2023 · Axsome Therapeutics' (AXSM-4.53%) psychiatric drug Auvelity could reach blockbuster status by the end of the decade -- if the company can pull through its current cash crunch. It had just over ...

fool.com

$90.00
OFF

Analysts Are Bullish On These Healthcare Stocks: Axsome Therapeutics ...

2 weeks from now

Feb 7, 2024 · Axsome Therapeutics (AXSM) Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics on February 2 and set a price target of $90.00. The company’s shares closed ...

businessinsider.com

14%
OFF

A Glimpse Into The Expert Outlook On Axsome Therapeutics …

2 weeks from now

Aug 5, 2024 · Net Margin: Axsome Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -91.14%, the …

nasdaq.com

100%
OFF

After Jumping 100%, Is Axsome A Buy Before 2023?

2 weeks from now

Dec 16, 2022 · It delivered $16.8 million in sales during its first full quarter at Axsome, and prescriptions rose 15%. If Sunosi continues at this pace, annual sales of the drug could climb in the double digits ...

fool.com

$116.42
OFF

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

2 weeks from now

19 analysts have given Axsome Therapeutics (AXSM) a consensus rating of Buy while the Axsome Therapeutics (AXSM) price prediction in 2025 is $116.42 ... Axsome Therapeutics …

public.com

$1.34
OFF

Axsome Therapeutics (AXSM) Earnings Date And Reports 2025

2 weeks from now

Axsome Therapeutics issued Q3 2024 earnings on November 12, 2024, reporting an EPS of -$1.34, which beat analysts' consensus estimates of -$1.38 by $0.04. Quarterly revenue was …

marketbeat.com

$105
OFF

What Is The Current Price Target And Forecast For Axsome Therapeutics ...

2 weeks from now

5 days ago · The forecasts for Axsome Therapeutics, Inc. (AXSM) range from a low of $105 to a high of $180. The average price target represents a increase of $63.87 from the last closing price of $80.05.

zacks.com

FAQs about Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 … Coupon?

Will Axsome Therapeutics (axsm) see a year-over-year decline in earnings?

Wall Street expects a year-over-year decline in earnings on higher revenues when Axsome Therapeutics (AXSM) reports results for the quarter ended September 2024. ...

When is Axsome Therapeutics's next earnings report?

Axsome Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, August 7th, 2023. Axsome Therapeutics will be holding an earnings conference call on Monday, August 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call.. When is Axsome Therapeutics's earnings date? ...

How much money does Axsome Therapeutics make a year?

Axsome Therapeutics (NASDAQ:AXSM) has a recorded annual revenue of $50.04 million. How much profit does Axsome Therapeutics generate each year? Axsome Therapeutics (NASDAQ:AXSM) has a recorded net income of -$187.13 million. AXSM has generated -$3.80 earnings per share over the last four quarters. ...

Is Axsome (Axsome) a good stock to buy?

For Axsome, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -7.45%. On the other hand, the stock currently carries a Zacks Rank of #4. ...

Will a knockoff of Axsome cause Teva stock to tumble?

Teva Pharmaceutical ( TEVA) said Monday it plans a competing knockoff of Axsome Therapeutics ' ( AXSM) new depression treatment, leading AXSM stock to tumble. Axsome only just gained Food and Drug Administration approval for Auvelity in August. ...

What is the Zacks consensus estimate for a biopharmaceutical company?

Zacks Consensus Estimate This biopharmaceutical company is expected to post quarterly loss of $1.38 per share in its upcoming report, which represents a year-over-year change of -4.6%. Revenues are expected to be $98.71 million, up 70.8% from the year-ago quarter. Estimate Revisions Trend ...